Welcome to our dedicated page for CONCENTRA GROUP HOLDINGS PAREN SEC filings (Ticker: CON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Healthcare filings can feel like medical charts: dense, technical, and mission-critical. Concentra Group Holdings Parent Inc.’s disclosures weave together workers’ compensation statutes, telemedicine economics, and clinic utilization data—details investors hunt for yet rarely find quickly. If you have ever typed “Concentra Group Holdings Parent Inc. SEC filings explained simply” or searched for the next “Concentra Group Holdings Parent Inc. quarterly earnings report 10-Q filing,” you already know the challenge.
Stock Titan solves it. Our AI reads every line of the Concentra Group Holdings Parent Inc. annual report 10-K simplified, highlights segment profitability, and flags compliance risks in seconds. Need real-time alerts? We stream “Concentra Group Holdings Parent Inc. Form 4 insider transactions real-time,” so you can track executive stock transactions before the market reacts. Interactive dashboards turn pages of accounting notes into clear charts, while plain-English summaries answer the question: “What changed this quarter?”
The platform covers every filing type the moment it hits EDGAR: 10-K, 10-Q, 8-K material events explained, Form 4 insider trading transactions, and the proxy statement executive compensation breakdown. Use AI-powered summaries to compare clinic revenue trends, monitor workers’ comp claim costs, or assess telemedicine adoption—all without wading through footnotes. Whether you’re performing a Concentra Group Holdings Parent Inc. earnings report filing analysis or simply understanding Concentra Group Holdings Parent Inc. SEC documents with AI, our tools let you move from data to decision faster.
Concentra Group Holdings Parent (CON) reported a director’s equity award on Form 4. On 11/04/2025, the reporting person acquired 7,748 shares of Common Stock at $0, disclosed as a grant of restricted stock. Following the transaction, the director beneficially owns 20,740 shares, held directly.
The restricted stock grant will vest in full on November 4, 2026, subject to stated exceptions. This filing reflects an equity compensation event rather than an open‑market purchase.
Concentra Group Holdings Parent, Inc. disclosed an insider equity grant. On 11/04/2025, an officer received 60,000 shares of common stock as restricted stock at $0 under a grant that vests in equal annual installments over four years. Following the award, the reporting person beneficially owns 120,000 shares, held directly. The filer is the company’s Executive Vice President, Chief Digital & Data Officer. Transaction code: A (grant).
Concentra Group Holdings Parent, Inc. (CON) reported an insider equity grant. A company officer filed a Form 4 showing acquisition of 60,000 shares of common stock as a restricted stock grant at $0 on 11/04/2025. Following this grant, the officer directly beneficially owns 120,000 shares. The award will vest in equal annual installments over four years.
Concentra Group Holdings Parent, Inc. (CON) disclosed an insider equity grant. A director received 7,748 shares of common stock on 11/04/2025 at $0 as a restricted stock award that will vest in full on 11/04/2026.
Following this grant, the reporting person beneficially owns 20,740 shares, held directly.
Concentra Group Holdings Parent, Inc. (CON) reported a director equity award on a Form 4. On 11/04/2025, the director acquired 15,496 shares of common stock via two restricted stock grants at a stated price of $0.
One grant covered 7,748 shares that vest in equal annual installments over five years. A second grant covered 7,748 shares that, subject to certain exceptions, vest in full on November 4, 2026, the first anniversary of the grant date. Following these grants, the Form 4 shows 15,496 shares beneficially owned directly.
Concentra Group Holdings Parent, Inc. reported higher Q3 results. Revenue reached $572.8 million versus $489.6 million a year ago, and net income attributable to the company was $48.3 million versus $44.3 million. Basic and diluted EPS were $0.38 compared with $0.37.
Year to date, revenue was $1.624 billion versus $1.435 billion, while net income attributable to the company was $131.7 million versus $145.0 million. Operating cash flow was $160.7 million; cash ended at $49.9 million after investing $394.7 million, driven mainly by acquisitions.
The company completed the Nova Medical Centers acquisition for $265.0 million and the Pivot Onsite Innovations acquisition for $54.4 million. Q3 revenue included Nova $31.3 million and Pivot $16.6 million. Debt consisted of $650.0 million 6.875% senior notes and credit facilities including a Term Loan with $945.3 million principal outstanding; the revolver provided $393.0 million availability. The reported leverage ratio was 3.6x. The network operated 628 occupational health centers and 413 onsite clinics as of September 30, 2025.
Concentra Group Holdings Parent, Inc. announced two capital return actions alongside furnishing its third‑quarter results materials. The Board declared a cash dividend of $0.0625 per share, payable on or about December 9, 2025 to stockholders of record as of the close of business on December 2, 2025.
The Board also authorized a share repurchase program of up to $100 million of common stock, expiring on December 31, 2027. Repurchases may occur in the open market or through privately negotiated transactions, and the program will be funded with cash on hand. The company furnished a press release and financial presentation for the quarter ended September 30, 2025 as exhibits.
Concentra Group Holdings Parent, Inc. — Form 10-Q (Quarter ended June 30, 2025)
Q2 2025 revenue rose to $550.8 million versus $477.9 million in Q2 2024 (+~15%). Six-month revenue was $1,051.5 million versus $945.5 million. Despite revenue growth, net income attributable to the company declined to $44.6 million for the quarter (Q2 2024: $51.7 million); EPS fell to $0.35 (Q2 2024: $0.50). Cash declined to $73.9 million from $183.3 million at year-end 2024.
Material corporate actions: acquisition of Nova Medical Centers (closed March 1, 2025) for a preliminary purchase price of $265.0 million and Pivot Onsite Innovations (closed June 1, 2025) for $54.4 million. Goodwill increased materially (preliminary goodwill of $206.96M and $34.43M). Company amended credit facilities (revolver increased to $450M; incremental term loan $102.1M); net leverage was 3.8x (covenant 6.5x). AOCI shows $3.9 million loss from hedges. Significant contingencies include a multi-million patient data-breach class action matter and DOJ inquiry regarding physical therapy billing; outcomes are uncertain. Board declared a $0.0625/share dividend payable Aug 28, 2025.
Concentra Group Holdings Parent, Inc. (CON) furnished a press release and financial schedules announcing results for the quarter ended June 30, 2025 (Exhibit 99.1) and published a related presentation (Exhibit 99.2) on August 7, 2025. The filing states these items are furnished under Item 2.02 and Item 7.01 and are not "filed" for purposes of Section 18 of the Exchange Act.
Dividend: On August 6, 2025, the Board declared a cash dividend of $0.0625 per share, payable on or about August 28, 2025, to stockholders of record at the close of business on August 21, 2025. Exhibits listed in the report are 99.1 (press release), 99.2 (presentation) and 104 (Cover Page iXBRL). The report is signed by Timothy Ryan, Executive Vice President and Chief Legal Counsel, dated August 7, 2025.